Guide — Sleep Medicine
Obesity Hypoventilation Syndrome (OHS)
OHS is a triad: obesity, daytime alveolar hypoventilation with chronic hypercapnia, and sleep-disordered breathing — diagnosed only after other causes of hypoventilation have been excluded. Historically called Pickwickian syndrome, it is frequently missed until the patient presents in acute respiratory failure.
10 min read · Sleep Medicine
Written by Apex Respiratory Editorial Team
Educational use only. This material supports respiratory therapy education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional protocols, or physician orders. Always follow facility policies and current provider orders, and verify calculations independently before clinical use.
Overview
Obesity hypoventilation syndrome is defined by three criteria that must all be present:
- Obesity— body mass index ≥30 kg/m²
- Daytime alveolar hypoventilation— awake resting PaCO₂ ≥45 mm Hg at sea level (chronic hypercapnia)
- Sleep-disordered breathing— obstructive sleep apnea in ~90% of cases; a minority have sleep-related hypoventilation without significant OSA
Critically, OHS is a diagnosis of exclusion. Other causes of hypoventilation — severe COPD, neuromuscular disease, hypothyroidism, and chest-wall disease — must be ruled out before the diagnosis stands. The condition was historically called Pickwickian syndrome.
Key Concepts — Pathophysiology
Three mechanisms converge to produce the chronic daytime hypercapnia that defines OHS:
- Mechanical load.Excess adipose tissue on the chest wall and abdomen increases the work of breathing, reduces chest-wall compliance, and restricts diaphragm excursion — raising the energy cost of every breath.
- Blunted central ventilatory response to CO₂. Patients with OHS mount a diminished respiratory drive in response to rising PaCO₂, so they fail to compensate for the extra mechanical load with increased ventilation.
- Leptin resistance. Leptin normally stimulates ventilation; in obesity, leptin resistance reduces this respiratory-stimulating effect, further blunting the drive to breathe.
The result is chronic underventilation even while awake, with nocturnal hypoventilation superimposed — worst during REM sleep when muscle tone is lowest. About 90% of OHS patients also have obstructive sleep apnea, often severe.
Assessment & Findings
The key diagnostic finding is daytime hypercapnia in an obese patient with sleep-disordered breathing. Pure OSA produces a normal daytime PaCO₂ — that distinction is the pivotal test in any workup.
| Finding | Significance |
|---|---|
| Awake PaCO₂ ≥45 mm Hg | Defines OHS; not present in pure OSA |
| Chronic respiratory acidosis on ABG | Elevated PaCO₂ + compensatory elevated HCO₃⁻ + near-normal pH; daytime hypoxemia common |
| Serum HCO₃⁻ ≥27 mEq/L | Inexpensive screening clue to chronic hypercapnia; prompts ABG evaluation |
| Nocturnal desaturation | Worse during REM; profound in advanced disease |
| Pulmonary hypertension / cor pulmonale | Right heart failure, secondary polycythemia, and peripheral edema signal advanced disease |
Clinical Pearl
An elevated serum bicarbonate (HCO₃⁻ ≥27 mEq/L) is a useful, inexpensive screening flag for chronic hypercapnia — if you see it in an obese patient with sleep complaints, order an arterial blood gas before assuming pure OSA.
RT Priorities & Interventions
- PAP therapy is first-line. CPAP is often effective for stable OHS when concurrent severe OSA is the dominant mechanism. Bilevel PAP (BiPAP, often with a backup rate / noninvasive ventilation) is indicated for patients who remain hypercapnic or hypoxemic on CPAP, or who have sleep-related hypoventilation without significant OSA.
- Add supplemental oxygen as needed. PAP alone may not fully correct hypoxemia, especially in advanced disease with pulmonary hypertension.
- Weight loss is the definitive long-term treatment. Lifestyle modification, pharmacologic management, and bariatric surgery can all improve or resolve OHS by reducing the mechanical load on the respiratory system.
- Avoid sedatives. Agents that blunt respiratory drive (benzodiazepines, opioids) are dangerous in patients who are already chronically underventilating.
- Use cautious, titrated oxygen in acute hypercapnic decompensation. Uncontrolled high-flow O₂ can worsen hypercapnia via the Haldane effect and loss of hypoxic drive. Target SpO₂ 88–92% until ventilatory support is established.
- Acute-on-chronic hypercapnic respiratory failure requires noninvasive ventilation (bilevel PAP or NIV), sometimes in the ICU. This presentation is common precisely because OHS is frequently undiagnosed at baseline.
Common Pitfalls
- Attributing the hypercapnia to “just OSA.” Obstructive sleep apnea alone does NOT cause daytime hypercapnia. If a patient with OSA has an elevated PaCO₂ while awake, OHS (or another cause) must be actively sought.
- Giving uncontrolled high-flow oxygen without ventilatory support. In a patient with chronic hypercapnia, high-flow O₂ can precipitate CO₂ narcosis. Always pair supplemental oxygen with NIV during acute decompensation.
- Under-recognition before crisis.OHS is frequently missed until the patient arrives in acute respiratory failure. An elevated serum HCO₃⁻ in an obese patient with daytime sleepiness should trigger an ABG — don’t wait for decompensation.
- Expecting CPAP to fully correct hypoventilation.When the primary problem is reduced ventilatory drive — rather than airway obstruction alone — pressure support (bilevel PAP) is needed. A patient who remains hypercapnic on CPAP should be escalated to bilevel.
Board Exam Pearls
- OHS definition on exams: BMI ≥30 kg/m² + awake PaCO₂ ≥45 mm Hg + sleep-disordered breathing, with other causes of hypoventilation excluded. All three criteria required.
- An elevated serum HCO₃⁻ (≥27 mEq/L) is the classic screening clue to chronic hypercapnia; it triggers the ABG that makes the diagnosis.
- Pure OSA = normal daytime CO₂. OHS = elevated daytime CO₂. This distinction drives both diagnosis and treatment escalation from CPAP to bilevel/NIV.
- PAP is first-line; bilevel/NIV is reserved for persistent hypercapnia on CPAP or for sleep-related hypoventilation without significant OSA. Substantial weight loss (including bariatric surgery) is the definitive long-term treatment.
- In acute hypercapnic decompensation: NIV + controlled low-flow O₂. High-flow oxygen without ventilatory support risks CO₂ narcosis — a classic exam trap.
FAQ
What defines obesity hypoventilation syndrome?
Obesity (BMI ≥30 kg/m²), daytime chronic hypercapnia (awake PaCO₂ ≥45 mm Hg), and sleep-disordered breathing, once other causes of hypoventilation have been excluded.
How is OHS different from obstructive sleep apnea?
OSA alone produces a normal daytime CO₂. OHS adds daytime hypercapnia — though about 90% of OHS patients also have OSA.
Why is the daytime CO₂ high in OHS?
The combined load of obesity on the chest wall, a blunted ventilatory response to CO₂, and leptin resistance leave the patient chronically underventilated even while awake.
What is the treatment for OHS?
Positive airway pressure (CPAP, or bilevel/NIV if still hypercapnic), supplemental oxygen as needed, and weight loss — with bariatric surgery as a definitive option.
Practice with real values
The daytime ABG is the defining test for OHS — use the ABG Interpreter to confirm chronic respiratory acidosis, check metabolic compensation, and distinguish OHS from pure OSA at the bedside.
Open the ABG Interpreter →Related Resources
Sources
- Kacmarek RM, Stoller JK, Heuer AJ. Egan's Fundamentals of Respiratory Care. 12th ed. Elsevier; 2021.
- Mokhlesi B, Masa JF, Brozek JL, et al. Evaluation and management of obesity hypoventilation syndrome. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2019;200(3):e6-e24.